Non-Small Cell Lung Carcinoma Market Growth Overview
The non-small cell lung carcinoma (NSCLC) market, valued at $8.27 billion in 2023, is projected to reach $21.51 billion by 2033, growing at a CAGR of 10.03%. This growth is fueled by ongoing clinical research, new treatment developments, and the increasing prevalence of NSCLC.
Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5155
Key Takeaways
- North America led the non-small lung carcinoma market in 2023 and is expected to maintain its dominance throughout the forecast period.
- Asia Pacific is anticipated to experience the fastest growth in the market between 2024 and 2033.
- Adenocarcinoma was the leading type in the market in 2023.
- The squamous cell carcinoma segment is expected to grow at the fastest rate during the forecast period.
- Targeted therapy was the dominant treatment in 2023, while immunotherapy is projected to see significant growth in the coming years.
- Hospital pharmacies were the leading distribution channel for NSCLC treatments in 2023.
Industry Overview
Non-small cell lung cancer (NSCLC) is the most common form of lung cancer, accounting for approximately 85% of all cases. This cancer develops in the lung tissue and, though it progresses more slowly than small-cell lung cancer, it often spreads to other areas by the time it’s diagnosed. Early detection and treatment are crucial for better outcomes.
The rising prevalence of lung cancer, largely driven by smoking, air pollution, exposure to industrial chemicals, radiation, and tuberculosis, is fueling the growth of the NSCLC market. Diagnostic tools such as lab tests, X-rays, CT scans, biopsies, and bronchoscopy are essential for detecting NSCLC and contribute to the market’s growth. Following diagnosis, treatments, hospital stays, monitoring, and post-treatment care add to the growing demand for healthcare services, driving the market forward. With increasing NSCLC cases, the need for ongoing testing, treatments, and recovery solutions will continue to rise.
Top Companies in the Non-Small Cell Lung Carcinoma (NSCLC) Market
- Eli Lilly and Company
A global pharmaceutical company known for its cancer treatments, including those for NSCLC, focusing on targeted therapies and immunotherapies. - Celgene Corporation (Now part of Bristol-Myers Squibb)
Previously an independent company, now part of Bristol-Myers Squibb, Celgene developed key treatments for cancer, including NSCLC. - AstraZeneca
Known for treatments like Tagrisso and Imfinzi, AstraZeneca is a leader in NSCLC therapies, especially for targeted therapies. - Bristol-Myers Squibb Company
This company is known for Opdivo and Yervoy, which are popular immunotherapies for NSCLC. - Novartis AG
Novartis focuses on innovative cancer treatments and has therapies like Kisqali for NSCLC. - Sanofi
Sanofi is involved in developing biologic drugs and targeted therapies for NSCLC. - Merck & Co., Inc.
Merck is known for Keytruda, a leading immunotherapy used in NSCLC treatment. - F. Hoffmann-La Roche Ltd.
Roche offers therapies like Tecentriq and Xalkori for treating NSCLC. - Pfizer Inc.
Pfizer develops cancer therapies, including treatments for NSCLC, with a focus on precision medicine. - Boehringer Ingelheim
This company focuses on lung cancer therapies, including Vargatef, for advanced NSCLC treatment.
Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/non-small-lung-carcinoma-market-sizing
Access exclusive insight now @ https://www.towardshealthcare.com/price/5155
We’ve prepared a service to support you. Please feel free to contact us at sales@towardshealthcare.com
Web: https://www.towardshealthcare.com
Visit Dental Specifics: https://www.towardsdental.com
Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription
For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare
